High-Affinity Oncogene-Specific Monoclonal Antibodies

The biological detection and measurement of oncogene-related proteins in samples becomes possible through Creative Diagnostics Oncogene-Specific Monoclonal Antibodies which provide reliable high-performance results. The antibodies undergo advanced hybridoma production and screening optimization to achieve superior sensitivity and specificity and reliable results. The antibodies undergo complete validation to ensure reliable performance and stable operation and precise target detection. The Oncogene-Specific Monoclonal Antibodies serve multiple purposes in cancer research and biomarker identification and therapeutic target verification and clinical diagnostic applications to support precision oncology and drug development and personalized medicine.

Talk to our experts Available Products

Why Choose Creative Diagnostics' Oncogene-Specific Monoclonal Antibodies?

The Oncogene-Specific Monoclonal Antibodies from Creative Diagnostics enable precise detection of oncogene-associated proteins in biological samples through their high sensitivity and specificity. The antibodies undergo advanced antibody engineering and quality control validation to provide precise results with consistent performance and long-term stability. The antibodies serve multiple applications in cancer diagnosis and biomarker identification and therapeutic target verification and oncology scientific investigations. Our product advantages:

• The products shows high specificity because it precisely detects and attaches to oncogene-related proteins while preventing unwanted binding to non-specific proteins.
• The products shows high sensitivity because it identifies rare tumor-associated proteins which enables researchers to detect cancer at its earliest stages.
• The production process depends on a dependable manufacturing system and strict quality control procedures to achieve consistent results between batches.
• The product has been functionally validated for use in multiple applications including IHC, Western blotting, ELISA and flow cytometry.
• The system shows robust stability because it maintains stable operation during both long-term storage and experimental testing.
• The products finds applications across multiple scientific domains which include cancer research and diagnostic development and therapeutic target validation and drug screening.
• The method delivers results that can be duplicated because it produces highly consistent data which supports research and clinical testing.

Get a Quote

Case Study

The research on lung cancer uses Oncogene-Specific Monoclonal Antibodies to study the disease.

Background

Non-small cell lung cancer (NSCLC) develops through genetic changes that include EGFR mutations and ALK gene fusions which lead to uncontrolled tumor expansion. The identification and study of oncogene-related proteins requires immediate attention because it enables better early detection methods and targeted treatment development.

Approach

Scientists used Oncogene-Specific Monoclonal Antibodies that specifically targeted mutant EGFR and ALK fusion proteins. The researchers used immunohistochemistry (IHC) and western blotting tests to assess oncogene expression in tumor tissue samples and cell lines. The researchers conducted multiple validation tests to reach high sensitivity and specificity levels while obtaining reliable results.

Results

• The antibodies proved able to differentiate between normal EGFR proteins and different mutant forms of EGFR.
• The ALK-specific monoclonal antibodies showed reliable performance in detecting tumors with ALK-positive status which matched the results from genomic sequencing tests.
• The results from different testing runs showed high consistency which proved the excellent reproducibility of the method.

Impact

The research proves Oncogene-Specific Monoclonal Antibodies function as essential instruments for:

• The detection of tumors that develop because of oncogenes enables early cancer diagnosis.
• The antibodies help researchers validate therapeutic targets which leads to improved drug development.

Conclusion

The study shows Oncogene-Specific Monoclonal Antibodies enable doctors to divide patients into groups for precision medicine treatment through EGFR and ALK inhibitor selection.